Table 1.
Patients’ characteristics: CML samples used for in vitro studies and response to ‘asciminib+ponatinib’
| Patient no. | Age (years) | Gender | Source | CML phase | BCR-ABL1 mutations | Therapy before cell sampling | ‘asciminib+ponatinib’ |
|---|---|---|---|---|---|---|---|
| #1 | 54 | f | PB | CP | n.t. | none | Synergistic (p); Cooperative CD34+/CD38- (a-fc) |
| #2 | 27 | m | PB | CP | n.t. | none | Synergistic (p) Cooperative CD34+/CD38- (a-fc) |
| #3 | 19 | m | PB | CP | n.t. | none | Synergistic (p); Cooperative CD34+/CD38- (a-fc) |
| #4 | 34 | f | PB | CP | n.t. | none | Synergistic (p) |
| #5 | 36 | m | PB | CP | n.t. | none | Synergistic (p) |
| #6 | 25 | f | PB | CP | n.t. | Imatinib (dis.) | Synergistic (p) |
| #7 | 46 | f | PB | CP | n.t. | none | Synergistic (p) |
| #8 | 52 | f | PB | CP | n.t. | none | Cooperative (p) |
| #9 | 31 | m | BM | BP | T315I | Imatinib (res.) | Cooperative CD34+/CD38- (a-fc) |
| Dasatinib (res.) | |||||||
| #10 | 48 | f | BM | BP | T315I | Dasatinib (res.) | Cooperative CD34+/CD38- (a-fc) |
| #11 | 43 | m | PB | BP | V299L/F317L | Imatinib (res.) | Synergistic CD34+/CD38- (a-fc) |
| Dasatinib (res.) | |||||||
| CHT+GO HSCT |
No., number; f, female; m, male; PB, peripheral blood; BM, bone marrow; CP, chronic phase; BP, blast phase; n.t.: not tested; dis: discontinued by the patient; res, resistant; CHT: polychemotherapy; GO: gemtuzumab ozogamycin; HSCT: hematopoietic stem cell transplantation. The in vitro response of leukemic cells to the combination ‘asciminib+ponatinib’ was assessed by 3H-thymidine uptake experiments (cell proliferation: p) and/or by determination of apoptotic CD34+/CD38- stem-cells by Annexin V-FITC/DAPI staining and flow cytometry (a-fc).